Market Access Impact (EU5) [Asthma/COPD]
|市場進入的課題:氣喘、COPD (歐盟5國) Market Access Impact (EU5) [Asthma/COPD]|
|出版日期: 2017年07月01日||內容資訊: 英文||
Market barriers cost most brands share, but awareness is a bigger issue for some
In the EU5 countries, market barriers affect a modest 15% of asthma/COPD prescriptions, but they're siphoning market share from most of the brands we surveyed. That lost share goes to a handful of brands, putting the market leaders even further ahead. Meanwhile some brands have a bigger problem: doctors aren't prescribing them because they don't know they exist.
Market Access Impact: Asthma/COPD (EU5) shows you how widely prescribed your brand is, and reveals how 7 barriers affect your market share. You'll learn how much share you win and lose, who you take share from, and who gets your lost share.
Based on a survey of 150 pulmonologists, the report covers 11 major therapies from AstraZeneca, Boehringer Ingelheim, GSK, and Novartis.
Market Access Impact: Asthma/COPD (EU5) explores key issues affecting drug manufacturers. You'll learn:
How barriers affect market access:
How barriers affect your brand:
We surveyed 150 pulmonologists-30 from each EU5 country (France, Italy, Germany, Spain, UK)-chosen from the largest community of validated physicians in the world.
All respondents have:
We conducted the survey between June 1st and 5th, 2017.